The immunological, environmental, and phylogenetic perpetrators of metastatic leishmaniasis

Trends in Parasitology

Volumn 30, Issue 8, 2014, Pages 412-422

  Hartley, Mary Anne ^a   Drexler, Stefan ^a   Ronet, Catherine ^a   Beverley, Stephen M ^b   Fasel, Nicolas ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cutaneous leishmaniasis; Leishmania RNA virus; Metastatic leishmaniasis; Pattern recognition receptor; Post kala azar dermal leishmaniasis; Toll like receptor

Indexed keywords

BETA INTERFERON; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PATTERN RECOGNITION RECEPTOR; RECEPTOR; RETINOIC ACID INDUCIBLE GENE 1 LIKE RECEPTOR; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; GENETIC POLYMORPHISM; HOST PARASITE INTERACTION; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INNATE IMMUNITY; LEISHMANIA; LOCALIZED CUTANEOUS LEISHMANIASIS; METASTASIS POTENTIAL; METASTATIC LEISHMANIASIS; MULTIFACTORIAL INHERITANCE; NONHUMAN; PARASITE LOAD; PHENOTYPIC VARIATION; PHYLOGENY; POST KALA AZAR DERMAL LEISHMANIASIS; PROTEIN POLYMORPHISM; REVIEW; RISK FACTOR; SKIN LEISHMANIASIS; SKIN METASTASIS;

NASO HEXACANTHUS; RNA VIRUSES;

CUTANEOUS LEISHMANIASIS; LEISHMANIA RNA VIRUS; METASTATIC LEISHMANIASIS; PATTERN RECOGNITION RECEPTOR; POST-KALA-AZAR DERMAL LEISHMANIASIS; TOLL-LIKE RECEPTOR;

ENVIRONMENT; GLOBAL WARMING; HUMANS; IMMUNITY, INNATE; LEISHMANIASIS, CUTANEOUS; PHYLOGENY; RISK FACTORS;

EID: 84904752533     PISSN: 14714922     EISSN: 14715007     Source Type: Journal    
DOI: 10.1016/j.pt.2014.05.006     Document Type: Review

References (102)

1. World Health Organization Control of the leishmaniases. WHO Tech. Rep. Ser. 2010, 949:1-186.
2. van Griensven J., et al. Leishmaniasis in immunosuppressed individuals. Clin Microbiol. Infect. 2014, 20:286-299.
3. Hotez P.J., et al. Neglected tropical diseases of the Middle East and North Africa: review of their prevalence, distribution, and opportunities for control. PLoS Negl. Trop. Dis. 2012, 6:e1475.
4. Jacobson R.L. Leishmaniasis in an era of conflict in the Middle East. Vector Borne Zoonotic Dis. 2011, 11:247-258.
5. Mendonca M.G., et al. Persistence of Leishmania parasites in scars after clinical cure of American cutaneous leishmaniasis: is there a sterile cure?. J. Infect. Dis. 2004, 189:1018-1023.
6. Alvar J., et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE 2012, 7:e35671.
7. Goto H., Lindoso J.A. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev. Anti Infect. Ther. 2010, 8:419-433.
8. Murray H.W., et al. Advances in leishmaniasis. Lancet 2005, 366:1561-1577.
9. Zijlstra E.E., et al. Post-kala-azar dermal leishmaniasis. Lancet Infect. Dis. 2003, 3:87-98.
10. Mondal D., Khan M.G. Recent advances in post-kala-azar dermal leishmaniasis. Curr. Opin. Infect. Dis. 2011, 24:418-422.
11. Lynn M.A., McMaster W.R. Leishmania: conserved evolution - diverse diseases. Trends Parasitol. 2008, 24:103-105.
12. Depledge D.P., et al. Comparative expression profiling of Leishmania: modulation in gene expression between species and in different host genetic backgrounds. PLoS Negl. Trop. Dis. 2009, 3:e476.
13. Smith D.F., et al. Comparative genomics: from genotype to disease phenotype in the leishmaniases. Int. J. Parasitol. 2007, 37:1173-1186.
14. Rogers M.B., et al. Chromosome and gene copy number variation allow major structural change between species and strains of Leishmania. Genome Res. 2011, 21:2129-2142.
15. Acestor N., et al. Resistance to oxidative stress is associated with metastasis in mucocutaneous leishmaniasis. J. Infect. Dis. 2006, 194:1160-1167.
16. Souza A.S., et al. Resistance of Leishmania (Viannia) braziliensis to nitric oxide: correlation with antimony therapy and TNF-α production. BMC Infect. Dis. 2010, 10:209.
17. Arevalo J., et al. Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis. J. Infect. Dis. 2007, 195:1846-1851.
18. Dey A., Singh S. Genetic heterogeneity among visceral and post-Kala-Azar dermal leishmaniasis strains from eastern India. Infect. Genet. Evol. 2007, 7:219-222.
19. Subba Raju B.V., et al. Genetic fingerprinting and identification of differentially expressed genes in isolates of Leishmania donovani from Indian patients of post-kala-azar dermal leishmaniasis. Parasitology 2008, 135:23-32.
20. Salotra P., et al. Upregulation of surface proteins in Leishmania donovani isolated from patients of post kala-azar dermal leishmaniasis. Microbes Infect. 2006, 8:637-644.
21. Figueroa R.A., et al. Detection of Leishmania in unaffected mucosal tissues of patients with cutaneous leishmaniasis caused by Leishmania (Viannia) species. J. Infect. Dis. 2009, 200:638-646.
22. Postorino M.C., et al. Visceral leishmaniasis reactivation in transplant patients: a minireview with report of a new case. J. Nephrol. 2011, 24:530-534.
23. Ives A., et al. Leishmania RNA virus controls the severity of mucocutaneous leishmaniasis. Science 2011, 331:775-778.
24. Martinez J.E., et al. Clonal diversity in the expression and stability of the metastatic capability of Leishmania guyanensis in the golden hamster. J. Parasitol. 2000, 86:792-799.
25. Zangger H., et al. Detection of Leishmania RNA virus in Leishmania parasites. PLoS Negl. Trop. Dis. 2013, 7:e2006.
26. Zangger H., et al. Leishmania aethiopica field isolates bearing an endosymbiontic dsRNA virus induce pro-inflammatory cytokine response. PLoS Negl. Trop. Dis. 2014, 8:e2836.
27. Pereira Lde O., et al. Severity of tegumentary leishmaniasis is not exclusively associated with Leishmania RNA virus 1 infection in Brazil. Mem. Inst. Oswaldo Cruz 2013, 108:665-667.
28. Oliveira A.G., et al. Influence of the nutritional status in the clinical and therapeutical evolution in adults and elderly with American Tegumentary Leishmaniasis. Acta Trop. 2013, 128:36-40.
29. Khalil E.A., et al. Post-kala-azar dermal Leishmaniasis: a paradigm of paradoxical immune reconstitution syndrome in non-HIV/AIDS patients. J. Trop. Med. 2013, 2013:275253.
30. Mukhopadhyay D., et al. Post kala-azar dermal leishmaniasis: an unresolved mystery. Trends Parasitol. 2014, 30:65-74.
31. Naik S., et al. Compartmentalized control of skin immunity by resident commensals. Science 2012, 337:1115-1119.
32. Wortmann G.W., et al. Cutaneous leishmaniasis following local trauma: a clinical pearl. Clin. Infect. Dis. 2000, 31:199-201.
33. Kawai T., Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011, 34:637-650.
34. Mock D.J., et al. Leishmania induces survival, proliferation and elevated cellular dNTP levels in human monocytes promoting acceleration of HIV co-infection. PLoS Pathog. 2012, 8:e1002635.
35. Lodge R., et al. HIV-1 promotes intake of Leishmania parasites by enhancing phosphatidylserine-mediated, CD91/LRP-1-dependent phagocytosis in human macrophages. PLoS ONE 2012, 7:e32761.
36. Faria M.S., et al. Toll-like receptors in Leishmania infections: guardians or promoters?. J. Parasitol. Res. 2012, 2012:930257.
37. Soong L. Subversion and utilization of host innate defense by Leishmania amazonensis. Front. Immunol. 2012, 3:58.
38. Muraille E., et al. Genetically resistant mice lacking MyD88-adapter protein display a high susceptibility to Leishmania major infection associated with a polarized Th2 response. J. Immunol. 2003, 170:4237-4241.
39. Vargas-Inchaustegui D.A., et al. CXCL10 production by human monocytes in response to Leishmania braziliensis infection. Infect. Immun. 2010, 78:301-308.
40. Revaz-Breton M., et al. The MyD88 protein 88 pathway is differently involved in immune responses induced by distinct substrains of Leishmania major. Eur. J. Immunol. 2010, 40:1697-1707.
41. Schamber-Reis B.L., et al. UNC93B1 and nucleic acid-sensing Toll-like receptors mediate host resistance to infection with Leishmania major. J. Biol. Chem. 2013, 288:7127-7136.
42. Carvalho L.P., et al. Lymph node hypertrophy following Leishmania major infection is dependent on TLR9. J. Immunol. 2012, 188:1394-1401.
43. Abou Fakher F.H., et al. TLR9-dependent activation of dendritic cells by DNA from Leishmania major favors Th1 cell development and the resolution of lesions. J. Immunol. 2009, 182:1386-1396.
44. Weinkopff T., et al. Role of Toll-like receptor 9 signaling in experimental Leishmania braziliensis infection. Infect. Immun. 2013, 81:1575-1584.
45. Ives A., et al. MyD88 and TLR9 dependent immune responses mediate resistance to Leishmania guyanensis infections, irrespective of Leishmania RNA virus burden. PLoS ONE 2014, 9:e96766.
46. Ramirez C., et al. Human macrophage response to L (Viannia) panamensis: microarray evidence for an early inflammatory response. PLoS Negl. Trop. Dis. 2012, 6:e1866.
47. Hartley M.A., et al. Leishmania RNA virus: when the host pays the toll. Front. Cell. Infect. Microbiol. 2012, 2:99.
48. Hartley M.A., et al. The therapeutic potential of immune cross-talk in leishmaniasis. Clin. Microbiol. Infect. 2013, 19:119-130.
49. Hotz C., Bourquin C. Systemic cancer immunotherapy with Toll-like receptor 7 agonists: timing is everything. Oncoimmunology 2012, 1:227-228.
50. Vanhoutte F., et al. Toll-like receptor (TLR)2 and TLR3 synergy and cross-inhibition in murine myeloid dendritic cells. Immunol. Lett. 2008, 116:86-94.
51. Whitmore M.M., et al. Negative regulation of TLR-signaling pathways by activating transcription factor-3. J. Immunol. 2007, 179:3622-3630.
52. Martinon F., et al. The inflammasomes: guardians of the body. Annu. Rev. Immunol. 2009, 27:229-265.
53. Meylan E., et al. Intracellular pattern recognition receptors in the host response. Nature 2006, 442:39-44.
54. Lima-Junior D.S., et al. Inflammasome-derived IL-1β production induces nitric oxide-mediated resistance to Leishmania. Nat. Med. 2013, 19:909-915.
55. Becker C.E., O'Neill L.A. Inflammasomes in inflammatory disorders: the role of TLRs and their interactions with NLRs. Semin. Immunopathol. 2007, 29:239-248.
56. Marques-da-Silva C., et al. Infection with Leishmania amazonensis upregulates purinergic receptor expression and induces host-cell susceptibility to UTP-mediated apoptosis. Cell. Microbiol. 2011, 13:1410-1428.
57. Khouri R., et al. IFN-β impairs superoxide-dependent parasite killing in human macrophages: evidence for a deleterious role of SOD1 in cutaneous leishmaniasis. J. Immunol. 2009, 182:2525-2531.
58. Meissner F., et al. Superoxide dismutase 1 regulates caspase-1 and endotoxic shock. Nat. Immunol. 2008, 9:866-872.
59. Mahmoudian Sani M., et al. Evaluation of the expression of the inflammasome pathway related components in Leishmania major-infected murine macrophages. Eur. J. Exp. Biol. 2013, 3:104-109.
60. Santos D.M., et al. PLGA nanoparticles loaded with KMP-11 stimulate innate immunity and induce the killing of Leishmania. Nanomedicine 2013, 9:985-995.
61. Carvalho L.P., et al. Differential immune regulation of activated T cells between cutaneous and mucosal leishmaniasis as a model for pathogenesis. Parasite Immunol. 2007, 29:251-258.
62. Faria D.R., et al. Decreased in situ expression of interleukin-10 receptor is correlated with the exacerbated inflammatory and cytotoxic responses observed in mucosal leishmaniasis. Infect. Immun. 2005, 73:7853-7859.
63. +-mediated parasite killing in human cutaneous leishmaniasis. J. Invest. Dermatol. 2013, 133:1533-1540.
64. Novais F.O., et al. Cytotoxic T cells mediate pathology and metastasis in cutaneous leishmaniasis. PLoS Pathog. 2013, 9:e1003504.
65. Maretti-Mira A.C., et al. Therapeutic failure in American cutaneous leishmaniasis is associated with gelatinase activity and cytokine expression. Clin. Exp. Immunol. 2011, 163:207-214.
66. Maretti-Mira A.C., et al. MMP-9 activity is induced by Leishmania braziliensis infection and correlates with mucosal leishmaniasis. Acta Trop. 2011, 119:160-164.
67. Silva-Almeida M., et al. Extracellular matrix alterations in experimental Leishmania amazonensis infection in susceptible and resistant mice. Vet. Res. 2012, 43:10.
68. Diaz Y.R., et al. T-bet, GATA-3, and Foxp3 expression and Th1/Th2 cytokine production in the clinical outcome of human infection with Leishmania (Viannia) species. J. Infect. Dis. 2010, 202:406-415.
69. Castilho T.M., et al. Murine model of chronic L (Viannia) panamensis infection: role of IL-13 in disease. Eur. J. Immunol. 2010, 40:2816-2829.
70. Couppie P., et al. Disseminated cutaneous leishmaniasis due to Leishmania guyanensis: case of a patient with 425 lesions. Am. J. Trop. Med. Hyg. 2004, 71:558-560.
71. Bourreau E., et al. Intralesional regulatory T-cell suppressive function during human acute and chronic cutaneous leishmaniasis due to Leishmania guyanensis. Infect. Immun. 2009, 77:1465-1474.
72. Schonian G., et al. Genetic variability within the species Leishmania aethiopica does not correlate with clinical variations of cutaneous leishmaniasis. Mol. Biochem. Parasitol. 2000, 106:239-248.
73. Kumar D., et al. Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine. Ann. Trop. Med. Parasitol. 2009, 103:727-730.
74. Ansari N.A., et al. Interferon (IFN)-γ, tumor necrosis factor-α, interleukin-6, and IFN-γ receptor 1 are the major immunological determinants associated with post-kala azar dermal leishmaniasis. J. Infect. Dis. 2006, 194:958-965.
75. Castellucci L., et al. CXCR1 and SLC11A1 polymorphisms affect susceptibility to cutaneous leishmaniasis in Brazil: a case-control and family-based study. BMC Med. Genet. 2010, 11:10.
76. Ramasawmy R., et al. The -2518bp promoter polymorphism at CCL2/MCP1 influences susceptibility to mucosal but not localized cutaneous leishmaniasis in Brazil. Infect. Genet. Evol. 2010, 10:607-613.
77. Castellucci L., et al. IL6-174 G/C promoter polymorphism influences susceptibility to mucosal but not localized cutaneous leishmaniasis in Brazil. J. Infect. Dis. 2006, 194:519-527.
78. Castellucci L., et al. FLI1 polymorphism affects susceptibility to cutaneous leishmaniasis in Brazil. Genes Immun. 2011, 12:589-594.
79. de Jesus Fernandes Covas C., et al. Candidate gene case-control and functional study shows macrophage inhibitory factor (MIF) polymorphism is associated with cutaneous leishmaniasis. Cytokine 2013, 61:168-172.
80. Al-Qahtani A., et al. Toll-like receptor 3 polymorphism and its association with hepatitis B virus infection in Saudi Arabian patients. J. Med. Virol. 2012, 84:1353-1359.
81. Ghoshal A., et al. 9-O-acetylated sialic acids enhance entry of virulent Leishmania donovani promastigotes into macrophages. Parasitology 2009, 136:159-173.
82. Salhi A., et al. Immunological and genetic evidence for a crucial role of IL-10 in cutaneous lesions in humans infected with Leishmania braziliensis. J. Immunol. 2008, 180:6139-6148.
83. Petzl-Erler M.L., et al. Association of mucosal leishmaniasis with HLA. Hum. Immunol. 1991, 32:254-260.
84. Okwor I., et al. The immunology of Leishmania/HIV co-infection. Immunol. Res. 2013, 56:163-171.
85. Andreani G., et al. Mechanisms of interaction between protozoan parasites and HIV. Curr. Opin. HIV AIDS 2012, 7:276-282.
86. Barreto-de-Souza V., et al. Increased Leishmania replication in HIV-1-infected macrophages is mediated by tat protein through cyclooxygenase-2 expression and prostaglandin E2 synthesis. J. Infect. Dis. 2006, 194:846-854.
87. Danaher R.J., et al. HIV protease inhibitors alter innate immune response signaling to double-stranded RNA in oral epithelial cells: implications for immune reconstitution inflammatory syndrome?. AIDS 2010, 24:2587-2590.
88. Cabrera M., et al. Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis. J. Exp. Med. 1995, 182:1259-1264.
89. Drexler S.K., Foxwell B.M. The role of Toll-like receptors in chronic inflammation. Int. J. Biochem. Cell Biol. 2010, 42:506-518.
90. Moumad K., et al. Genetic polymorphisms in host innate immune sensor genes and the risk of nasopharyngeal carcinoma in North Africa. G3 (Bethesda) 2013, 3:971-977.
91. Li G., Zheng Z. Toll-like receptor 3 genetic variants and susceptibility to hepatocellular carcinoma and HBV-related hepatocellular carcinoma. Tumour Biol. 2013, 34:1589-1594.
92. Qian F., et al. Impaired Toll-like receptor 3-mediated immune responses from macrophages of patients chronically infected with hepatitis C virus. Clin. Vaccine Immunol. 2013, 20:146-155.
93. Sironi M., et al. A common polymorphism in TLR3 confers natural resistance to HIV-1 infection. J. Immunol. 2012, 188:818-823.
94. Barreiro L.B., et al. Evolutionary dynamics of human Toll-like receptors and their different contributions to host defense. PLoS Genet. 2009, 5:e1000562.
95. Ogura Y., et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001, 411:603-606.
96. Hugot J.P., et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001, 411:599-603.
97. Girardin S.E., et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem. 2003, 278:8869-8872.
98. Wang B.X., Fish E.N. The yin and yang of viruses and interferons. Trends Immunol. 2012, 33:190-197.
99. Wilson E.B., Brooks D.G. Decoding the complexity of type I interferon to treat persistent viral infections. Trends Microbiol. 2013, 21:634-640.
100. Bogdan C., et al. The role of type I interferons in non-viral infections. Immunol. Rev. 2004, 202:33-48.
101. Mattner J., et al. Protection against progressive leishmaniasis by IFN-β. J. Immunol. 2004, 172:7574-7582.
102. Xin L., et al. Type I IFN receptor regulates neutrophil functions and innate immunity to Leishmania parasites. J. Immunol. 2010, 184:7047-7056.